tagraxofusp 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
fusion proteins 5323 2055491-00-2

Description:

MoleculeDescription

Synonyms:

  • elzonris
  • tagraxofusp
  • tagraxofusp-erzs
  • SL-401
  • DT388IL3
  • Molecule 129
Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 7, 2021 EMA STEMLINE THERAPEUTICS B.V.
Dec. 21, 2018 FDA STEMLINE THERAPEEUTICS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Capillary leak syndrome 158.83 47.73 21 121 2746 90625559

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Capillary leak syndrome 413.74 56.92 63 482 2644 42618146

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Capillary leak syndrome 445.23 53.34 65 539 4843 110583852

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX67 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA CS M0005633 Cytotoxins
FDA EPC N0000193862 Cytotoxin
FDA EPC N0000193864 CD123 Interaction
FDA MoA N0000193865 CD123 Interactions
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs
adagrasibafliberceptaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitox show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Blastic plasmacytoid dendritic cell neoplasm indication 445105005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Elongation factor 2 Enzyme UNKNOWN
Interleukin-3 receptor Membrane receptor BINDING AGENT UNKNOWN DRUG LABEL

External reference:

IDSource
8ZHS5657EH UNII
4038207 VANDF
4038208 VANDF
C4746084 UMLSCUI
CHEBI:757048 CHEBI
CHEMBL4297573 ChEMBL_ID
DB14731 DRUGBANK_ID
D11358 KEGG_DRUG
10770 INN_ID
C000592123 MESH_SUPPLEMENTAL_RECORD_UI
783435000 SNOMEDCT_US
783577002 SNOMEDCT_US
303404 MMSL
35833 MMSL
d09110 MMSL
017871 NDDF
2109054 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Elzonris HUMAN PRESCRIPTION DRUG LABEL 1 72187-0401 INJECTION, SOLUTION 1000 ug INTRAVENOUS BLA 26 sections